For comparison, Pfizer reported yesterday that Abrysvo made full-year sales of $890 million, which - while respectable - were well below its competitor. However, it brought in $515 million in the ...

It teased the positive results in July. Along with Beyfortus (nirsevimab), it is also a potential rival to Pfizer's RSV vaccine Abrysvo, which can be given to women during pregnancy to protect ...

No writing assistance was utilized in the production of this manuscript. Worldwide, respiratory syncytial virus (RSV) is the most important cause of bronchiolitis and pneumonia in infants.

While two vaccines are available - Abrysvo and Arexvy - the Centers for Disease Control and Prevention doesn't recommend one over the other.

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Of the 647 patients, 414 (64.0%) received Pfizer's RSV prefusion F protein–based (RSVpreF) vaccine during pregnancy. The vaccine is commercially available as Abrysvo. Several factors were associated ...